公开(公告)号：US20240207372A1

公开(公告)日：2024-06-27

申请号：US18361724

申请日：2023-07-28

Applicant: Thornhill Therapeutics, Inc.

Inventor： Randall J. Mrsny ,  Tahir Mahmood

IPC: A61K38/45 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K38/26 ,  A61K38/27 ,  A61K38/48 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/54 ,  C07K16/24

CPC classification number: A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.

公开(公告)号：US20240299565A1

公开(公告)日：2024-09-12

申请号：US18502473

申请日：2023-11-06

Applicant: Thornhill Therapeutics, Inc.

Inventor： Keyi Liu ,  Julia Dawn Mackay ,  Weijun Feng ,  Thomas Carl Hunter ,  Randall J. Mrsny

IPC: A61K47/64 ,  A61K9/00 ,  A61K38/21 ,  A61K38/27 ,  A61K47/65

CPC classification number: A61K47/6415 ,  A61K9/0043 ,  A61K9/007 ,  A61K38/21 ,  A61K38/27 ,  A61K47/65

Abstract: The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering the biologically active cargo via transcytosis transport across an epithelial cell; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.

公开(公告)号：US20240238429A1

公开(公告)日：2024-07-18

申请号：US18241744

申请日：2023-09-01

Applicant: Thornhill Therapeutics, Inc

Inventor： Randall J. Mrsny ,  Tahir Mahmood ,  Charles Olson ,  Weijun Feng

IPC: A61K47/64 ,  A61K38/20 ,  A61P1/00 ,  C07K1/18

CPC classification number: A61K47/642 ,  A61K38/20 ,  A61P1/00 ,  C07K1/18

Abstract: The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.